Journal of Clinical Endocrinology & Metabolism, Vol 81, 2801-2804, Copyright © 1996 by Endocrine Society

ARTICLES

Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo

M Boscaro, C Betterle, M Volpato, F Fallo, J Furmaniak, B Rees Smith and N Sonino
Division of Endocrinology, University of Padova, Italy.

Adrenal autoantibodies (ACA) are markers of adrenal cortex involvement in idiopathic Addison's disease. Recently the 21-hydroxylase (21-OH) enzyme has been discovered to be the major autoantigen of the ACA. A potential role of these antibodies in determining adrenal failure by inhibition of the 21-OH has been recently postulated. To test this hypothesis, cortisol and aldosterone (final products of adrenal steroid synthesis) and 17-hydroxyprogesterone (17-OH-progesterone) (as a marker of 21-OH impairment) have been investigated in baseline conditions and after ACTH (1-24) stimulation test in a group of 42 patients positive for both ACA and 21-OH autoantibodies. Patients were divided into five groups according to the stages (0-4) of adrenal failure. With progression toward overt Addison's disease, baseline 17-OH- progesterone, cortisol, and aldosterone remained almost unchanged but with impairment of their responses to ACTH (1-24) stimulation. The 17- OH-progesterone/cortisol ration remained normal both in basal conditions and after stimulation at stages 0-3. At stage 4 (overt Addison's disease), this ratio increased in baseline condition with no changes after ACTH (1-24), probably because of persistent 17-OH- progesterone gonadal production. In conclusion, there was a progressive and concomitant impairment of the synthesis of all steroids tested over various phases of adrenal failure. The pattern of response of the 17-OH- progesterone/cortisol ratio to ACTH stimulation in patients with 21-OH autoantibodies was not consistent with the autoantibodies inhibiting the 21-OH activity. This suggests that the inhibiting effect of 21-OH autoantibodies on 21-OH activity is not usually evident in vivo.

This article has been cited by other articles:

				E. S. Husebye, E. Bratland, G. Bredholt, M. Fridkin, M. Dayan, and E. Mozes The Substrate-Binding Domain of 21-Hydroxylase, the Main Autoantigen in Autoimmune Addison's Disease, Is an Immunodominant T Cell Epitope Endocrinology, May 1, 2006; 147(5): 2411 - 2416. [Abstract] [Full Text] [PDF]

				C. K. Welt, A. Falorni, A. E. Taylor, K. A. Martin, and J. E. Hall Selective Theca Cell Dysfunction in Autoimmune Oophoritis Results in Multifollicular Development, Decreased Estradiol, and Elevated Inhibin B Levels J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3069 - 3076. [Abstract] [Full Text] [PDF]

				L Nikfarjam, S Kominami, T Yamazaki, S Chen, R Hewer, C Dal Pra, T Nakamatsu, C Betterle, R Zanchetta, B Rees Smith, et al. Mechanism of inhibition of cytochrome P450 C21 enzyme activity by autoantibodies from patients with Addison's disease Eur. J. Endocrinol., January 1, 2005; 152(1): 95 - 101. [Abstract] [Full Text] [PDF]

				A. De Bellis, A. Falorni, S. Laureti, S. Perrino, C. Coronella, F. Forini, E. Bizzarro, A. Bizzarro, G. Abbate, and A. Bellastella Time Course of 21-Hydroxylase Antibodies and Long-Term Remission of Subclinical Autoimmune Adrenalitis after Corticosteroid Therapy: Case Report J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 675 - 678. [Abstract] [Full Text]

				S. Laureti, A. De Bellis, V. I. Muccitelli, F. Calcinaro, A. Bizzarro, R. Rossi, A. Bellastella, F. Santeusanio, and A. Falorni Levels of Adrenocortical Autoantibodies Correlate with the Degree of Adrenal Dysfunction in Subjects with Preclinical Addison's Disease J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3507 - 3511. [Abstract] [Full Text]

				C. Betterle, M. Volpato, B. R. Smith, J. Furmaniak, S. Chen, N. A. Greggio, M. Sanzari, F. Tedesco, B. Pedini, M. Boscaro, et al. I. Adrenal Cortex and Steroid 21-Hydroxylase Autoantibodies in Adult Patients with Organ-Specific Autoimmune Diseases: Markers of Low Progression to Clinical Addison's Disease J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 932 - 938. [Abstract] [Full Text] [PDF]